Tango Therapeutics Statistics
Want to see TNGX full AI Analyst Report?
Tango Therapeutics (TNGX) Stock Statistics & Valuation Metrics
Total Valuation
Tango Therapeutics has a market cap or net worth of $4.21B. The enterprise value is $3.39B.
- Market Cap
- $4.21B
- Enterprise Value
- $3.39B
Share Statistics
Tango Therapeutics has 169,455,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 169,455,150
- Owned by Insiders
- 1.48%
- Owned by Institutions
- 49.94%
Financial Efficiency
Tango Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -29.31%.
- Return on Equity (ROE)
- -0.29
- Return on Assets (ROA)
- -0.25
- Return on Invested Capital (ROIC)
- -29.31%
- Return on Capital Employed (ROCE)
- -0.30
- Revenue Per Employee
- 455.36K
- Profits Per Employee
- -741.56K
- Employee Count
- 137
- Asset Turnover
- 0.16
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Tango Therapeutics is -18.48. Tango Therapeutics’s PEG ratio is 0.31.
- PE Ratio
- -18.48
- PS Ratio
- 0.00
- PB Ratio
- 4.52
- Price to FCF
- -28.73
- Price to Operating Cash Flow
- -29.55
- PEG Ratio
- 0.31
Income Statement
In the last 12 months, Tango Therapeutics had revenue of 62.38M and earned -101.59M in profits. Earnings per share was -0.87.
- Revenue
- 62.38M
- Gross Profit
- 60.10M
- Operating Income
- -111.29M
- Pretax Income
- -101.59M
- Net Income
- -101.59M
- EBITDA
- -99.31M
- Earnings Per Share (EPS)
- -0.87
Cash Flow
In the last 12 months, operating cash flow was -150.09M and capital expenditures -299,000, giving a free cash flow of -150.39M billion.
- Operating Cash Flow
- -150.09M
- Free Cash Flow
- -150.39M
- Free Cash Flow per Share
- -0.86
Dividends & Yields
Tango Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3.48%
- Earnings Yield
- -4.69%
Stock Price Statistics
- Beta
- 1.70
- 52-Week Price Change
- 230.31%
- 50-Day Moving Average
- 23.42
- 200-Day Moving Average
- 22.96
- Relative Strength Index (RSI)
- 57.02
- Average Volume (3m)
- 3.43M
Important Dates
Tango Therapeutics upcoming earnings date is Mar 29, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 29, 2027
- Ex-Dividend Date
- ―
Financial Position
Tango Therapeutics as a current ratio of 16.32, with Debt / Equity ratio of 9.70%
- Current Ratio
- 16.32
- Quick Ratio
- 16.32
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- 0.79
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Tango Therapeutics has paid 4,000 in taxes.
- Income Tax
- 4,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
Tango Therapeutics EV to EBITDA ratio is -20.68, with an EV/FCF ratio of -28.36.
- EV to Sales
- 0.00
- EV to EBITDA
- -20.68
- EV to Free Cash Flow
- -28.36
- EV to Operating Cash Flow
- -28.42
Balance Sheet
Tango Therapeutics has $977.50M in cash and marketable securities with $31.18M in debt, giving a net cash position of $946.32M billion.
- Cash & Marketable Securities
- $977.50M
- Total Debt
- $31.18M
- Net Cash
- $946.32M
- Net Cash Per Share
- $5.58
- Tangible Book Value Per Share
- $5.64
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Tango Therapeutics is $45.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $45.14
- Price Target Upside
- 77.03% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- -49.92%
Scores
- Smart Score
- 9
- AI Score
- 47
